FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of veterinary internal medicine2016; 30(4); 1313-1321; doi: 10.1111/jvim.14371

Major Histocompatibility Complex I and II Expression and Lymphocytic Subtypes in Muscle of Horses with Immune-Mediated Myositis.

Abstract: Major histocompatibility complex (MHC) I and II expression is not normally detected on sarcolemma, but is detected with lymphocytic infiltrates in immune-mediated myositis (IMM) of humans and dogs and in dysferlin-deficient muscular dystrophy. Objective: To determine if sarcolemmal MHC is expressed in active IMM in horses, if MHC expression is associated with lymphocytic subtype, and if dysferlin is expressed in IMM. Methods: Twenty-one IMM horses of Quarter Horse-related breeds, 3 healthy and 6 disease controls (3 pasture myopathy, 3 amylase-resistant polysaccharide storage myopathy [PSSM]). Methods: Immunohistochemical staining for MHC I, II, and CD4+, CD8+, CD20+ lymphocytes was performed on archived muscle of IMM and control horses. Scores were given for MHC I, II, and lymphocytic subtypes. Immunofluorescent staining for dysferlin, dystrophin, and a-sarcoglycan was performed. Results: Sarcolemmal MHC I and II expression was detected in 17/21 and 15/21 of IMM horses, respectively, and in specific fibers of PSSM horses, but not healthy or pasture myopathy controls. The CD4+, CD8+, and CD20+ cells were present in 20/21 IMM muscles with CD4+ predominance in 10/21 and CD8+ predominance in 6/21 of IMM horses. Dysferlin, dystrophin, and a-sarcoglycan staining were similar in IMM and control muscles. Conclusions: Deficiencies of dysferlin, dystrophin, and a-sarcoglycan are not associated with IMM. Sarcolemmal MHC I and II expression in a proportion of myofibers of IMM horses in conjunction with lymphocytic infiltration supports an immune-mediated etiology for IMM. The MHC expression also occured in specific myofibers in PSSM horses in the absence of lymphocytic infiltrates.
Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2016-06-28 PubMed ID: 27352021PubMed Central: PMC5094553DOI: 10.1111/jvim.14371Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines the expression levels of the Major Histocompatibility Complex (MHC) I and II in the muscle tissues of horses suffering from immune-mediated myositis (IMM), a condition where the body’s immune system mistakenly attacks healthy muscle tissue. The study also investigates any potential correlation between MHC expression, specific types of lymphocytes and the muscle protective protein, dysferlin.

Research Objective

The research has a threefold objective.

  • First, it aims to determine if sarcolemmal MHC, a type of protein usually found on cell surfaces, is expressed in horses experiencing an active IMM episode.
  • Second, the researchers wanted to check whether MHC expression is associated with a particular subtype of lymphocytes, a type of immune cell.
  • Finally, the research seeks to ascertain if dysferlin, a muscle-protective protein, is expressed in IMM cases.

Methods

The study comprised of 21 IMM horses from Quarter Horse-related breeds, as well as 9 control horses (3 healthy, 3 with pasture myopathy, and 3 with polysaccharide storage myopathy [PSSM]). The researchers performed immunohistochemical staining on the archived muscle samples of these horses to determine the presence and levels of MHC I, II, and the lymphocyte subtypes CD4+, CD8+, and CD20+. Immunofluorescent staining was also done for proteins dysferlin, dystrophin, and a-sarcoglycan.

Findings

The researchers detected the expression of Sarcolemmal MHC I and II in the majority (17 out of 21 and 15 out of 21, respectively) of the IMM horses and in specific muscle fibers of PSSM horses, though such expressions weren’t found in healthy or pasture myopathy control horses. The lymphocyte subtypes were present in almost all IMM muscles, with CD4+ being predominant in 10 out of 21 cases, and CD8+ in 6 out of 21 cases. Meanwhile, the staining for dysferlin, dystrophin, and a-sarcoglycan was noted to be similar in both IMM cases and control horses.

Conclusions

The research concluded that there is no link between the deficiency of muscle-protective proteins dysferlin, dystrophin, and a-sarcoglycan with IMM. The presence of Sarcolemmal MHC I and II expression in muscle fibers of IMM horses, along with lymphocytic infiltration, supports the understanding that IMM is caused by an immune response. The expression of MHC was also found in specific muscle fibers of PSSM horses, even without noticeable lymphocytic infiltrates.

Cite This Article

APA
Durward-Akhurst SA, Finno CJ, Barnes N, Shivers J, Guo LT, Shelton GD, Valberg SJ. (2016). Major Histocompatibility Complex I and II Expression and Lymphocytic Subtypes in Muscle of Horses with Immune-Mediated Myositis. J Vet Intern Med, 30(4), 1313-1321. https://doi.org/10.1111/jvim.14371

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 30
Issue: 4
Pages: 1313-1321

Researcher Affiliations

Durward-Akhurst, S A
  • Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
Finno, C J
  • Department of Population Health and Reproduction, University of California-Davis, Davis, CA.
Barnes, N
  • Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
Shivers, J
  • Department of Veterinary Population Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN.
Guo, L T
  • Department of Pathology, University of California, San Diego, La Jolla, CA.
Shelton, G D
  • Department of Pathology, University of California, San Diego, La Jolla, CA.
Valberg, S J
  • Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI.

MeSH Terms

  • Animals
  • Gene Expression Regulation
  • Horse Diseases / metabolism
  • Horse Diseases / pathology
  • Horses
  • Lymphocyte Subsets
  • Major Histocompatibility Complex / genetics
  • Major Histocompatibility Complex / physiology
  • Muscle, Skeletal / cytology
  • Muscle, Skeletal / metabolism
  • Muscle, Skeletal / pathology
  • Myositis / immunology
  • Myositis / pathology
  • Myositis / veterinary

Grant Funding

  • K01 OD015134 / NIH HHS
  • L40 TR001136 / NCATS NIH HHS

References

This article includes 26 references
  1. Lewis SS, Valberg SJ, Nielsen IL. Suspected immune-mediated myositis in horses.. J Vet Intern Med 2007 May-Jun;21(3):495-503.
    pubmed: 17552457doi: 10.1892/0891-6640(2007)21[495:simih]2.0.co;2google scholar: lookup
  2. Pumarola M, Moore PF, Shelton GD. Canine inflammatory myopathy: analysis of cellular infiltrates.. Muscle Nerve 2004 Jun;29(6):782-9.
    pubmed: 15170610doi: 10.1002/mus.20043google scholar: lookup
  3. Evans J, Levesque D, Shelton GD. Canine inflammatory myopathies: a clinicopathologic review of 200 cases.. J Vet Intern Med 2004 Sep-Oct;18(5):679-91.
    pubmed: 15515585doi: 10.1892/0891-6640(2004)18<679:cimacr>2.0.co;2google scholar: lookup
  4. Hewer E, Goebel HH. Myopathology of non-infectious inflammatory myopathies - the current status.. Pathol Res Pract 2008;204(9):609-23.
    pubmed: 18514433doi: 10.1016/j.prp.2008.03.006google scholar: lookup
  5. Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients.. Neurology 2001 Dec 11;57(11):2136-8.
    pubmed: 11739845doi: 10.1212/wnl.57.11.2136google scholar: lookup
  6. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, Mantegazza R. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study.. J Neuroimmunol 2003 Sep;142(1-2):130-6.
    pubmed: 14512171doi: 10.1016/s0165-5728(03)00255-8google scholar: lookup
  7. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.. Ann Neurol 1988 Jan;23(1):64-72.
    pubmed: 3278673doi: 10.1002/ana.410230111google scholar: lookup
  8. Paciello O, Shelton GD, Papparella S. Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis.. Neuromuscul Disord 2007 Apr;17(4):313-20.
    pubmed: 17360184doi: 10.1016/j.nmd.2007.01.012google scholar: lookup
  9. Appleyard ST, Dunn MJ, Dubowitz V, Rose ML. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders.. Lancet 1985 Feb 16;1(8425):361-3.
    pubmed: 2857418doi: 10.1016/s0140-6736(85)91384-4google scholar: lookup
  10. McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases.. J Neurol Sci 1989 Feb;89(2-3):213-26.
    pubmed: 2926449doi: 10.1016/0022-510x(89)90023-3google scholar: lookup
  11. Hohlfield R. Immune mechanisms in muscle diseases. Myology: Basic and Clinical 3rd ed New York: McGraw‐Hill, Medical Publishing Division; 2004:889–914.
  12. Yin X, Wang Q, Chen T, Niu J, Ban R, Liu J, Mao Y, Pu C. CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.. Int J Clin Exp Pathol 2015;8(3):3069-75.
    pmc: PMC4440128pubmed: 26045819
  13. Cumming WJK. Color Atlas of Muscle Pathology. 1st ed London; Baltimore: Mosby‐Wolfe; 1994.
  14. Liu LA, Engvall E. Sarcoglycan isoforms in skeletal muscle.. J Biol Chem 1999 Dec 31;274(53):38171-6.
    pubmed: 10608889doi: 10.1074/jbc.274.53.38171google scholar: lookup
  15. Guo LT, Moore SA, Forcales S, Engvall E, Shelton GD. Evaluation of commercial dysferlin antibodies on canine, mouse and human skeletal muscle.. Neuromuscul Disord 2010 Dec;20(12):820-5.
    pubmed: 20817457doi: 10.1016/j.nmd.2010.07.278google scholar: lookup
  16. Shelton GD. From dog to man: the broad spectrum of inflammatory myopathies.. Neuromuscul Disord 2007 Oct;17(9-10):663-70.
    pubmed: 17629703doi: 10.1016/j.nmd.2007.06.466google scholar: lookup
  17. Morita T, Shimada A, Yashiro S, Takeuchi T, Hikasa Y, Okamoto Y, Mabuchi Y. Myofiber expression of class I major histocompatibility complex accompanied by CD8+ T-cell-associated myofiber injury in a case of canine polymyositis.. Vet Pathol 2002 Jul;39(4):512-5.
    pubmed: 12126158doi: 10.1354/vp.39-4-512google scholar: lookup
  18. Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, Tonali P. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies.. Clin Exp Immunol 1994 Jan;95(1):166-72.
    pmc: PMC1534629pubmed: 7507012doi: 10.1111/j.1365-2249.1994.tb06032.xgoogle scholar: lookup
  19. Shelton GD, Hoffman EP, Ghimbovschi S, Peters IR, Day MJ, Mullins M, Moore PF, Nagaraju K. Immunopathogenic pathways in canine inflammatory myopathies resemble human myositis.. Vet Immunol Immunopathol 2006 Sep 15;113(1-2):200-14.
    pubmed: 16797723doi: 10.1016/j.vetimm.2006.05.005google scholar: lookup
  20. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment.. Trends Immunol 2005 Jul;26(7):373-80.
    pubmed: 15922662doi: 10.1016/j.it.2005.05.003google scholar: lookup
  21. Jain A, Sharma MC, Sarkar C, Bhatia R, Singh S, Handa R. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies.. Arch Pathol Lab Med 2007 Jul;131(7):1070-6.
    pubmed: 17616993doi: 10.5858/2007-131-1070-mhcciagoogle scholar: lookup
  22. McCue ME, Armién AG, Lucio M, Mickelson JR, Valberg SJ. Comparative skeletal muscle histopathologic and ultrastructural features in two forms of polysaccharide storage myopathy in horses.. Vet Pathol 2009 Nov;46(6):1281-91.
    pubmed: 19605906doi: 10.1354/vp.08-vp-0177-m-flgoogle scholar: lookup
  23. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies.. J Neuropathol Exp Neurol 1996 Mar;55(3):342-7.
    pubmed: 8786392doi: 10.1097/00005072-199603000-00009google scholar: lookup
  24. Dalakas MC. Immunopathogenesis of inflammatory myopathies.. Ann Neurol 1995 May;37 Suppl 1:S74-86.
    pubmed: 8968219doi: 10.1002/ana.410370709google scholar: lookup
  25. Dalakas MC. Review: An update on inflammatory and autoimmune myopathies.. Neuropathol Appl Neurobiol 2011 Apr;37(3):226-42.
    pubmed: 21155862doi: 10.1111/j.1365-2990.2010.01153.xgoogle scholar: lookup
  26. Shinjo SK, Sallum AM, Silva CA, Marie SK. Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis.. Clinics (Sao Paulo) 2012 Aug;67(8):885-90.
    pmc: PMC3416892pubmed: 22948454doi: 10.6061/clinics/2012(08)05google scholar: lookup

Citations

This article has been cited 7 times.
  1. Ochala J, Finno CJ, Valberg SJ. Myofibre Hyper-Contractility in Horses Expressing the Myosin Heavy Chain Myopathy Mutation, MYH1(E321G). Cells 2021 Dec 6;10(12).
    doi: 10.3390/cells10123428pubmed: 34943936google scholar: lookup
  2. Gianino GM, Valberg SJ, Perumbakkam S, Henry ML, Gardner K, Penedo C, Finno CJ. Prevalence of the E321G MYH1 variant for immune-mediated myositis and nonexertional rhabdomyolysis in performance subgroups of American Quarter Horses. J Vet Intern Med 2019 Mar;33(2):897-901.
    doi: 10.1111/jvim.15393pubmed: 30623495google scholar: lookup
  3. Valberg SJ, Henry ML, Perumbakkam S, Gardner KL, Finno CJ. An E321G MYH1 mutation is strongly associated with nonexertional rhabdomyolysis in Quarter Horses. J Vet Intern Med 2018 Sep;32(5):1718-1725.
    doi: 10.1111/jvim.15299pubmed: 30079499google scholar: lookup
  4. Finno CJ, Gianino G, Perumbakkam S, Williams ZJ, Bordbari MH, Gardner KL, Burns E, Peng S, Durward-Akhurst SA, Valberg SJ. A missense mutation in MYH1 is associated with susceptibility to immune-mediated myositis in Quarter Horses. Skelet Muscle 2018 Mar 6;8(1):7.
    doi: 10.1186/s13395-018-0155-0pubmed: 29510741google scholar: lookup
  5. Boyle AG, Timoney JF, Newton JR, Hines MT, Waller AS, Buchanan BR. Streptococcus equi Infections in Horses: Guidelines for Treatment, Control, and Prevention of Strangles-Revised Consensus Statement. J Vet Intern Med 2018 Mar;32(2):633-647.
    doi: 10.1111/jvim.15043pubmed: 29424487google scholar: lookup
  6. Hunyadi L, Sundman EA, Kass PH, Williams DC, Aleman M. Clinical Implications and Hospital Outcome of Immune-Mediated Myositis in Horses. J Vet Intern Med 2017 Jan;31(1):170-175.
    doi: 10.1111/jvim.14637pubmed: 28044365google scholar: lookup
  7. Durward-Akhurst SA, Valberg SJ. Myosin Heavy Chain Myopathy and Immune-Mediated Muscle Disorders. Vet Clin North Am Equine Pract 2025 Apr;41(1):61-75.
    doi: 10.1016/j.cveq.2024.10.005pubmed: 39880733google scholar: lookup
Subscribe to our newsletter
Join 99,911 horse owners like you who receive our email updates on horse health and nutrition.